Robert Bals
Professor Robert Bals is a prominent researcher at the Universitätsklinikum des Saarlandes, known for his significant contributions to the field of respiratory medicine. He recently gained attention for leading a groundbreaking study that demonstrated the effectiveness of an azelastin-containing nasal spray in reducing COVID-19 infections by two-thirds, showcasing its potential as a preventative measure during high-risk periods.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 8.00 | 0.04% | +0% | 331,002,651 | 130,883 | $21,000,000 | 8,304$ |
| Luxembourg | 1 | 9.00 | 0.09% | +0% | 625,978 | 547 | $73,000 | 64$ |
| Estonia | 1 | 8.00 | 0.08% | +0% | 1,326,539 | 1,002 | $31,000 | 23$ |
| Totals | 3 | 332,955,168 | 132,432 | $21,104,000 | 8,391$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Estonia:
Robert Bals is the director of the Department of Internal Medicine at Saarland University Medical Center and led the study published in JAMA Internal Medicine.
8
United States:
Professor Robert Bals commented that the trial has demonstrated azelastine’s impact in a 'real-world setting.'
8
Luxembourg:
Professor Robert Bals from the University Hospital of Saarland led the study.
9